ReNeuron Group plc Director/PDMR Shareholding (3079O)
30 Janvier 2023 - 5:38PM
UK Regulatory
TIDMRENE
RNS Number : 3079O
ReNeuron Group plc
30 January 2023
ReNeuron Group plc
("ReNeuron" or "the Group")
Share Purchases by a Director and a PDMR
ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell
derived exosome technologies , announces that Barbara Staehelin,
Senior Independent Non-Executive Director and Suzanne Hancock, COO
and PDMR of the Company, have purchased 100,000 and 42,128
respectively of the Company's ordinary shares of 1p each ("Ordinary
Shares").
Name Title Number of Resulting Percentage
Ordinary beneficial of Company's
Shares purchased interest in Total Voting
the Company's Rights
Ordinary Shares
Senior Independent
Barbara Staehelin NED 100,000 270,000 0.472%
Chief Operations
Suzanne Hancock Officer 42,128 42,128 0.074%
-------------------- ------------------ ----------------- --------------
ENDS
Enquiries:
ReNeuron www.reneuron.com/investors
Iain Ross, Chairman Via Walbrook PR
John Hawkins, Chief Financial Officer
Liberum Capital Limited (NOMAD and
Joint Broker)
Phil Walker (Investment Banking)
Richard Lindley (Investment Banking)
Ben Cryer (Investment Banking) +44 (0)20 3100 2000
Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656
James Reeve/George Payne (Corporate
Finance)
Stefano Aquilino (Sales & Corporate
Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
Paul McManus / Alice Woodings +44 (0)7980 541 893 / +44 (0)7407 804
654
About ReNeuron
ReNeuron has developed a proprietary stem cell-derived,
exosome-based, drug delivery platform with customisable cellular
targeting capabilities for the delivery of complex drug
modalities.
Through the generation of several unique and scalable exosome
producer cell lines, our CustomEX(TM) platform can be optimised for
specific tissues targets and payloads leading to improvements in
therapeutic outcome and a reduction in off-target effects. ReNeuron
offers a delivery mechanism for a variety of payloads such as
siRNA, mRNA, proteins, small molecules and genes. Through its
conditionally immortalised induced pluripotent stem cell (iPSC)
platform, the Company can make allogeneic tissue cells of choice
and has the potential to produce exosomes with tissue specific
targeting ability.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
(Disclosure in relation to ordinary shares purchased by
Directors and PDMRs)
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Barbara Staehelin
--------------------------- --------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Senior Independent non-Executive Director
--------------------------- --------------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------- --------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
--------------------------- --------------------------------------------
b) LEI 2138003TU12CQ5TZO137
--------------------------- --------------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
--------------------------- --------------------------------------------
b) Nature of the transaction Acquisition of ordinary shares
--------------------------- --------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
10.20p 100,000
--------------------------- --------------------------------------------
d) Aggregated information 100,000 ordinary shares at an average price
of 10.20p at a total value of GBP10,200
--------------------------- --------------------------------------------
e) Date of the transaction 23 January 2023
--------------------------- --------------------------------------------
f) Place of the transaction London Stock Exchange AIM Market
--------------------------- --------------------------------------------
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
(Disclosure in relation to ordinary shares purchased by
Directors and PDMRs)
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Suzanne Hancock
--------------------------- ----------------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------
a) Position/status Chief Operations Officer/PDMR
--------------------------- ----------------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------- ----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name ReNeuron Group plc
--------------------------- ----------------------------------------------
b) LEI 2138003TU12CQ5TZO137
--------------------------- ----------------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
---------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
--------------------------- ----------------------------------------------
b) Nature of the transaction Acquisition of ordinary shares
--------------------------- ----------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
11.84p 42,128
--------------------------- ----------------------------------------------
d) Aggregated information 42,128 ordinary shares at an average price of
11.84p at a total value of GBP4,987.96
--------------------------- ----------------------------------------------
e) Date of the transaction 30 January 2023
--------------------------- ----------------------------------------------
f) Place of the transaction London Stock Exchange AIM Market
--------------------------- ----------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFVRLDIIVIV
(END) Dow Jones Newswires
January 30, 2023 11:38 ET (16:38 GMT)
Reneuron (LSE:RENE)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Reneuron (LSE:RENE)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025
